a 2016

Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 AXIS.

PAVLASOVÁ, Gabriela, Marek BORSKÝ, Václav ŠEDA, Kateřina ČERNÁ, Michael DOUBEK et. al.

Basic information

Original name

Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 AXIS.

Authors

Edition

XXX. Olomoucké hematologické dny, 2016

Other information

Type of outcome

Conference abstract

Confidentiality degree

is not subject to a state or trade secret

Organization unit

Central European Institute of Technology
Changed: 8/12/2016 13:04, Bc. Kateřina Kolesová

Links

LD15144, research and development project
Name: Buněčné a nebuněčné základy pro regeneraci kostí a zubů (Acronym: TissueENG)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1028/2015, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit III (Acronym: VýDiTeHeMa III)
Investor: Masaryk University, Category A
TE02000058, research and development project
Name: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED)
Investor: Technology Agency of the Czech Republic
16-29622A, interní kód MU
(CEP code: NV16-29622A)
Name: Vliv terapeutické inhibice BCR signalizace na genovou expresi u B buněčných malignit a její prognostický a prediktivní význam
Investor: Ministry of Health of the CR
692298, interní kód MU
Name: MEDGENET - Medical genomics and epigenomics network (Acronym: MEDGENET)
Investor: European Union, Spreading excellence and widening participation